Oppenheimer: Maintaining the Viracta Therapeutics (VIRX.US) rating, adjusted from being superior to better than the market rating, with a target price of $13.00.
奥本海默：维持Viracta Therapeutics(VIRX.US)评级，由优于大市调整至优于大市评级, 目标价13.00美元。
Oppenheimer: Maintaining the Viracta Therapeutics (VIRX.US) rating, adjusted from being superior to better than the market rating, with a target price of $13.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated